Developing and commercializing first-in-class, well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.

Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

- Phase 3 HDV D-LIVR (Lonafarnib) 75% Enrolled; Full Enrollment Planned in 2021 - Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 - Phase 3 COVID-19 TOGETHER Platform Study to Include Lambda Arm - $3.6M U.S. Zokinvy® Net Sales in Q1 2021 PALO ALTO, Calif.

Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study in Brazil

- Lambda arm to enroll up to 800 high-risk, non-hospitalized patients - Primary endpoint is reduction of emergency room visits and hospitalizations PALO ALTO, Calif. , May 3, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on

Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021

- Live Conference Call and Webcast at 4:30 PM ET PALO ALTO, Calif. , April 29, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare